NeuraSignal, Inc.

NeuraSignal is a medical technology company specializing in advanced transcranial Doppler (TCD) ultrasound systems enhanced through robotics, artificial intelligence, and cloud computing. Founded in 2013 and based in Los Angeles, the company develops FDA-cleared intelligent ultrasound platforms designed to automate and improve cerebral hemodynamics assessment for stroke detection, patent foramen ovale (PFO) screening, and vasospasm monitoring. The NG2 Intelligent Ultrasound system uses robotic control and machine learning algorithms to automatically locate the temporal window and lock onto cerebral blood flow signals with accuracy comparable to expert sonographers, while eliminating operator variability. The NeuraSignal Platform provides cloud connectivity enabling remote access, real-time data collaboration, and advanced analytics for clinical decision-making. Their portable Lucid™ TCD systems support both clinical deployment in hospital settings and international research initiatives. The technology is particularly valued in comprehensive stroke centers and neuroscience programs for its noninvasive nature, painless administration, and superior detection rates—clinical data demonstrates 3× shunt detection rates and 2.7× detection of intervenable shunts compared to standard transthoracic echocardiography (TTE).